CD8A and metastatic neoplasm: The optimized nanovaccines elicited robust priming of antigen‐specific CD8+ T cells and exerted strong antitumor efficacy against pre‐established local and metastatic tumors, demonstrating their potential for personalized cancer immunotherapy.